Cytokinetics, Incorporated (NASDAQ:CYTK) insider Caryn Gordon Mcdowell sold 13,181 shares of the business’s stock in a transaction dated Friday, October 6th. The shares were sold at an average price of $15.49, for a total value of $204,173.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Caryn Gordon Mcdowell also recently made the following trade(s):
- On Wednesday, September 6th, Caryn Gordon Mcdowell sold 10,131 shares of Cytokinetics, stock. The shares were sold at an average price of $14.60, for a total value of $147,912.60.
- On Tuesday, August 8th, Caryn Gordon Mcdowell sold 11,348 shares of Cytokinetics, stock. The shares were sold at an average price of $12.47, for a total value of $141,509.56.
Shares of Cytokinetics, Incorporated (CYTK) traded up 0.32% during trading on Tuesday, reaching $15.45. The company had a trading volume of 318,561 shares. Cytokinetics, Incorporated has a 1-year low of $8.77 and a 1-year high of $17.20. The company’s 50 day moving average is $14.35 and its 200-day moving average is $13.82. The stock’s market capitalization is $829.14 million.
Cytokinetics, (NASDAQ:CYTK) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.03). The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $5.28 million. Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. On average, equities research analysts anticipate that Cytokinetics, Incorporated will post ($2.51) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Cytokinetics, Incorporated (CYTK) Insider Caryn Gordon Mcdowell Sells 13,181 Shares” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://ledgergazette.com/2017/10/10/cytokinetics-incorporated-cytk-insider-caryn-gordon-mcdowell-sells-13181-shares.html.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd purchased a new stake in Cytokinetics, during the 2nd quarter valued at about $177,000. Sterling Capital Management LLC purchased a new stake in Cytokinetics, during the 2nd quarter valued at about $634,000. California State Teachers Retirement System grew its stake in Cytokinetics, by 10.3% during the 2nd quarter. California State Teachers Retirement System now owns 73,608 shares of the biopharmaceutical company’s stock valued at $891,000 after acquiring an additional 6,900 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Cytokinetics, by 20.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,708 shares of the biopharmaceutical company’s stock valued at $395,000 after acquiring an additional 5,490 shares in the last quarter. Finally, State Street Corp grew its stake in Cytokinetics, by 79.6% during the 2nd quarter. State Street Corp now owns 1,674,335 shares of the biopharmaceutical company’s stock valued at $20,259,000 after acquiring an additional 741,909 shares in the last quarter. Hedge funds and other institutional investors own 71.50% of the company’s stock.
A number of equities research analysts have recently weighed in on the company. BidaskClub raised Cytokinetics, from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Cytokinetics, in a research report on Sunday, September 17th. Morgan Stanley assumed coverage on Cytokinetics, in a research report on Monday, July 31st. They set an “overweight” rating and a $24.00 price target for the company. Zacks Investment Research lowered Cytokinetics, from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $21.00 price target on shares of Cytokinetics, in a research report on Monday, September 18th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Cytokinetics, currently has a consensus rating of “Buy” and a consensus target price of $21.64.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.